Bayer AG executives refused to be drawn into discussions about divesting the company’s material sciences business as it reported strong first quarter sales and earnings growth on April 28, driven by its newly launched pharmaceutical products and despite substantial currency exchange rate headwinds stemming from the rise in the value of the euro against major currencies.
Divesting its plastics-based material sciences unit would focus the German diversified company on its life sciences businesses in pharmaceuticals, crop...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?